MedTrace Logo

A Study of CIN-107 in Adults With Primary Aldosteronism

NCT04605549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-03

Study results available
· View outcomes & findings →

Summary

This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.

Conditions

  • Primary Aldosteronism
  • Hyperaldosteronism

Interventions

DRUG

CIN-107 2 mg dosing

One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.

DRUG

CIN-107 4 mg dosing

Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.

DRUG

CIN-107 8 mg dosing

Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-08
Primary Completion
2024-10-28
Completion
2024-10-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04605549 on ClinicalTrials.gov